Kura Oncology (KURA) Misses Q2 EPS by 34c

Kura Oncology (NASDAQ: KURA) reported Q2 EPS of ($0.75), $0.34 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $15.3 million versus the consensus estimate of $39.11 million.

For earnings history and earnings-related data on Kura Oncology (KURA) click here.

You May Also Be Interested In

• US's Greer Says Usmca Shifting To Rolling Talks, No Renewal - Bloomberg
• ServiceNow to report Q2 2026 results on July 22
• Asia AI Group files for 10M share Nasdaq IPO at $5 per share